»Go to related Japanese page in JPubb

Loading

Press Releases by "Takeda Pharmaceutical Company Limited"


You may also like to check companies from Takeda Pharmaceutical Company Limited's related industry or location as follows: Pharmaceuticals, Osaka

« Previous1234567Next »
1 - 50 of 347 for your search
Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Hodgkin Lymphoma at ASH Annual Meeting– Safety and Response Data Support Currently Enrolling Phase III Trial Evaluating ADCETRIS plus AVD Chemotherapy in Patients with Newly Diagnosed Hodgkin L...
[ Pharmaceuticals | 2012-12-11]
Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain AmyloidosisInvestigational MLN9708: first oral proteasome inhibitor in amyloidosis
[ Pharmaceuticals | 2012-12-11]
Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 studyMLN9708: First oral proteasome inhibitor to enter clinical evaluation in front-line multiple myeloma in combination with lenalidomide, dexamethasone
[ Pharmaceuticals | 2012-12-10]
Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas−Safety and Response Data Support Planned Phase III Trial in Front-line MTCL, Including Systemic Anaplastic Large Cell Lymphoma and Other Types of Peripheral T-cell Lymphomas ...
[ Pharmaceuticals | 2012-12-10]
Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma
[ Pharmaceuticals | 2012-12-10]
Takeda Announces the Establishment of New Organization with Appointment of its Leadership and Change of Organization Name
[ Pharmaceuticals | 2012-11-26]
VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium Pipeline Agents to be Featured at American Society of Hematology Annual Meeting- Data on MLN9708, ADCETRIS to be highlighted in multiple oral presentations −
[ Pharmaceuticals | 2012-11-06]
Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin)-- Indicated for use in adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma orrelapsed or refractory systemic anaplastic large cell lymphoma ---- First targeted treatm...
[ Pharmaceuticals | 2012-10-31]
Takeda Submits a New Drug Application for Cetilistat (Development Code: ATL-962)in Japan for the Treatment of Obesity with Complications
[ Pharmaceuticals | 2012-10-30]
DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
[ Pharmaceuticals | 2012-10-25]
Takeda to Acquire LigoCyte Pharmaceuticals, Inc.
[ Pharmaceuticals | 2012-10-05]
TAKEDA AND ADVINUS INITIATE MULTI-YEAR DRUG DISCOVERY COLLABORATION
[ Pharmaceuticals | 2012-10-03]
Takeda and Lundbeck Announce the U.S. Submission of a New Drug Application for Vortioxetine, an Investigational Drug for the Treatment of Major Depressive Disorder
[ Pharmaceuticals | 2012-10-02]
Pronova and Takeda Announce the New Drug Application Approval for Lotriga® 2g in Japanfor the Treatment of Hyperlipidemia
[ Pharmaceuticals | 2012-09-28]
Takeda has been selected for the third consecutive yearfor Dow Jones Sustainability Asia Pacific Index
[ Pharmaceuticals | 2012-09-26]
Takeda Completes its Russian Pharmaceutical Manufacturing Facility
[ Pharmaceuticals | 2012-09-12]
Revestive® (teduglutide) receives European marketing authorization for the treatment of adults with Short Bowel Syndrome (SBS)
[ Pharmaceuticals | 2012-09-05]
Companies Submit Joint Application Seeking Approval for Additional Indication forHelicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole
[ Pharmaceuticals | 2012-08-31]
Joint Research Agreement between the BC Cancer Agency and Takeda Pharmaceutical: Takeda to Initiate Joint Research at Shonan Incubation Laboratories
[ Pharmaceuticals | 2012-08-29]
Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) forCorporate Officers and Senior Management
[ Pharmaceuticals | 2012-08-28]
Takeda Announces Appointment of New Senior Leadership
[ Pharmaceuticals | 2012-08-27]
Agreement on Exclusive Distributorship for Sales of Johnson & Johnson's Non-prescription Drugs in Japan
[ Pharmaceuticals | 2012-08-03]
Takeda Initiates Phase 3 Trial of Motesanib in Japan and Additional Asian Countries-- Takeda obtains the exclusive worldwide rights to develop, manufacture and commercialize motesanib --
[ Pharmaceuticals | 2012-07-26]
Takeda and Millennium Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe-- Proposed indication for use in patients with relapsed or refractory CD30 positive Hodgkin lymphoma or relapsed or refractory systemic anaplastic large cell lymphoma --
[ Pharmaceuticals | 2012-07-23]
Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
[ Pharmaceuticals | 2012-07-18]
Takeda Completes Acquisition of Brazil’s MultilabPositions Takeda as a top ten pharmaceutical company in the world’s sixth largest economy
[ Pharmaceuticals | 2012-07-03]
Millennium Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma-- First oral proteasome inhibitor to enter phase 3 clinical trials --
[ Pharmaceuticals | 2012-06-29]
Takeda Obtains “Kurumin” Certification under Act to Support Raising Next-Generations Children
[ Pharmaceuticals | 2012-06-28]
Takeda Announces New Assignment of Directors, Appointment of Corporate Officers and Change of Senior Leadership
[ Pharmaceuticals | 2012-06-26]
Rienso® (ferumoxytol) receives European marketing authorisation for the treatment of iron deficiency anaemia in adult chronic kidney disease patients
[ Pharmaceuticals | 2012-06-25]
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for patients with Short Bowel Syndrome
[ Pharmaceuticals | 2012-06-25]
Takeda Announces Acceptance of European Medicines Agency Submissions for Two Fixed-Dose Combination Therapies, Alogliptin and Pioglitazone and Alogliptin and Metformin, for the Treatment of Type 2 Diabetes
[ Pharmaceuticals | 2012-06-20]
Takeda’s Exclusive Distribution of Pfizer Products in Japan
[ Pharmaceuticals | 2012-06-18]
Transfer of TAK-070, a Candidate Molecule for the Treatment of Alzheimer-type Dementia, to the National University Corporation
[ Pharmaceuticals | 2012-06-08]
Takeda Completes Acquisition of URL Pharma, Inc.
[ Pharmaceuticals | 2012-06-05]
Clinical Data Presented on Orteronel (TAK-700) without Steroids in Non-metastatic Prostate Cancer
[ Pharmaceuticals | 2012-06-05]
ASCO Presentations Highlight Preliminary Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Clinical Trials in Multiple Myeloma
[ Pharmaceuticals | 2012-06-04]
AZILVA® Now Available for a Treatment of Hypertension in Japan
[ Pharmaceuticals | 2012-05-28]
Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
[ Pharmaceuticals | 2012-05-25]
Takeda Announces the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes
[ Pharmaceuticals | 2012-05-24]
Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting- Presentations highlight first oral proteasome inhibitor in clinical trials in multiple myeloma patients -
[ Pharmaceuticals | 2012-05-24]
Takeda Included in the FTSE4Good Global Index for the Eighth Consecutive Year
[ Pharmaceuticals | 2012-05-21]
2012-2014 Mid-Range Plan - Continuing the “Transformation into a New Takeda” that promises Sustainable Growth -
[ Pharmaceuticals | 2012-05-11]
TAKEDA ANNOUNCES GEMINI II TRIAL OF VEDOLIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE MET PRIMARY ENDPOINTS OF IMPROVEMENT IN CLINICAL REMISSION IN INDUCTION AND MAINTENANCE PHASESPatients in the trial had failed at least one conventional therapy
[ Pharmaceuticals | 2012-05-11]
Takeda Submitted a Request for Reconsideration to the National Tax TribunalRelating to the Correction Notice on Transfer Pricing
[ Pharmaceuticals | 2012-05-07]
Takeda Receives Complete Response Letter from the FDA for Type 2 Diabetes Investigational Therapies Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone
[ Pharmaceuticals | 2012-04-26]
OMONTYS® (peginesatide) Injection Now Available for Adult Chronic Kidney Disease (CKD) Patients on Dialysis in the United States-- Only Once-Monthly Erythropoiesis-Stimulating Agent Launched in the United States --
[ Pharmaceuticals | 2012-04-25]
Takeda and AMAG Receive A Positive CHMP Opinion in Europe for Rienso® (ferumoxytol) for the Treatment of Iron Deficiency Anaemia in Adult Chronic Kidney Disease Patients
[ Pharmaceuticals | 2012-04-23]
Takeda to Acquire URL Pharma Acquisition Expands U.S. Business, Leadership in Gout
[ Pharmaceuticals | 2012-04-11]
Takeda Announces the Conclusion of Reinvestigation Relating to the Correction Notice on Transfer Pricing
[ Pharmaceuticals | 2012-04-06]
« Previous1234567Next »



You may also like to check companies from Takeda Pharmaceutical Company Limited's related industry or location as follows: Pharmaceuticals, Osaka

【Takeda Pharmaceutical Company Limited】
Stock Exchange
TSE1, OSE1, NSE1, SSE (Sapporo), FSE (Fukuoka)
Industry
Pharmaceuticals
Headquarter Location
Osaka
Official Website:
http://www.takeda.com/
Official Press-Release Page:
http://www.takeda.com/press/index.html
What's New
Top Searches

Keyword
1. FUJI XEROX SUSTAINABILITY REPORT RECEIVES GOLD AWARD IN SUSTAINABILITY REPORTING AWARDS IN 2012, SPONSORED BY TOYO KEIZAI, INC singapore
2. Starts Operations of Recycling System in South Korea, Australia and New Zealand to Reinforce Global Resource Recycling
3. Fuji Xerox Hong Kong Wins Gold Award at 2011 Hong Kong Awards for Environmental Excellence
4. okyu Land has acquired a luxury nursing home in Kami Yoga, Setagaya Ward, Tokyo
5. FUJI XEROX SUSTAINABILITY REPORT RECEIVES GOLD AWARD IN SUSTAINABILITY REPORTING AWARDS IN 2012, SPONSORED BY TOYO KEIZAI, INC

Company
1. Business Wire Japan
2. Boardwalk Inc.
3. Bank of Japan
4. Sharp Corporation
5. Tokyo Electric Power Company, Inc.

Industry
1. Media & Telecoms
2. Pharmaceuticals
3. Chemicals
4. Warehousing & Transportation
5. Wholesale

Prefecture
1. Tokyo
2. Aichi
3. Osaka
4. Aomori
5. Yamanashi

Stock Exchange
1. Q-Board
2. FSE (Fukuoka) ALL
3. NSE (Nagoya) ALL
4. SSE (Sapporo) ALL
5. OSE1

Press Conferense Videos
Sharp and Semiconductor Energy Laboratory Jointly Develop New Oxide Semiconductor Technology That Will Revolutionize Displays Sharp and Semiconductor Energy Laboratory Jointly Develop New Oxide Semiconductor Technology That Will Revolutionize Displays
Sharp Corporation 2012/06/01
More Videos
Latest Press Release Search

Save favorite searches Hot keywords

Fukushima | power supply | cloud | solar
*NOTE: Recommended keywords shown above.
Your Most Recently Viewed Companies
Visit any of the company pages in JPubb, and your most recently viewed companies will automatically show up here.

Erase all This feature:ON How to use
Most Popular: Takeda Pharmaceutical Company Limited
1. KAPIDEX™ (dexlansoprazole) Renamed DEXILANT™ in U.S. to Avoid Name Confusion
2010/03/05
2. Takeda Expands the Scope of its Corporate Venture Activitieswith the Formation of Takeda Ventures, Inc.
2010/10/29
Feed
Releases by Prefecture
Hokkaido | Aomori | Iwate | Miyagi | Akita | Yamagata | Fukushima

Ibaraki | Tochigi | Gunma | Saitama | Chiba | Tokyo | Kanagawa

Niigata | Toyama | Ishikawa | Fukui | Yamanashi | Nagano

Gifu | Shizuoka | Aichi | Mie

Shiga | Kyoto | Osaka | Hyogo | Nara | Wakayama

Tottori | Shimane | Okayama | Hiroshima | Yamaguchi

Tokushima | Kagawa | Ehime | Kochi

Fukuoka | Saga | Nagasaki | Kumamoto | Oita | Miyazaki | Kagoshima | Okinawa
Releases by Stock Exchange
TSE (Tokyo) All | TSE1 | TSE2 | Mothers

OSE (Osaka) All | OSE1 | OSE2 | JASDAQ Standard | JASDAQ Growth

NSE (Nagoya) All | NSE1 | NSE2 | Centrex | NSE-only

SSE (Sapporo) All | Ambitious | SSE-only

FSE (Fukuoka) All | Q-Board | FSE-only
Press Release Search
Company
Industry
Prefecture
Stock Exchange
Date
(yyyy/mm/dd)		 //～
//
Listed or Non-listed
*NOTE: Please input only items to be specified.
*NOTE: The "date" here means the one on which a press release is uploaded on this website. So it isn't necessarily the same as its official announcement date.
Company Search
Company
Industry
Prefecture
Stock Exchange
Listed or Non-listed
*NOTE: Please input only items to be specified.